UK markets close in 7 hours 32 minutes

Novo Nordisk A/S (0QIU.L)

LSE - LSE Delayed price. Currency in DKK
Add to watchlist
838.06+3.95 (+0.47%)
As of 05:45PM GMT. Market open.
Full screen
Previous close834.11
BidN/A x N/A
AskN/A x N/A
Day's range827.20 - 845.60
52-week range827.20 - 845.60
Avg. volumeN/A
Market cap19.902B
Beta (5Y monthly)0.32
PE ratio (TTM)0.39
EPS (TTM)21.50
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Novo Nordisk invests DKK 5.4 bn Danish kroner in expansion of clinical manufacturing facilities in Bagsværd, Denmark

    Bagsværd, Denmark, 22 November 2022 – Novo Nordisk today announced plans to invest 5.4 bn Danish kroner in the expansion of existing facilities in Bagsværd. The plans also include the construction of a new plant located in extension of the existing facilities. The investment will establish additional capacity in R&D for manufacturing of active pharmaceutical ingredients (API) to supply our global clinical trials. These expansions will provide capacity for developing Novo Nordisk’s future oral an

  • Globe Newswire

    Novo Nordisk A/S – Share repurchase programme

    Bagsværd, Denmark, 21 November 2022 – On 4 November 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programm

  • Globe Newswire

    Trading in Novo Nordisk shares by board members, executives and associated persons

    Bagsværd, Denmark, 15 November 2022 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their